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Abstract
Background: Glucagon-like peptide-1 (GLP-1) and its agonists are under assessment in treatment
of type 2 diabetes, by virtue of their antidiabetic actions, which include stimulation of insulin
secretion, inhibition of glucagon release, and delay of gastric emptying. We examined the potential
of GLP-1 to improve glycemic control in type 1 diabetes with no endogenous insulin secretion.
Methods: Dose-finding studies were carried out to establish mid range doses for delay of gastric
emptying indicated by postponement of pancreatic polypeptide responses after meals. The selected
dose of 0.63 micrograms/kg GLP-1 was administered before breakfast and lunch in 8-hour studies
in hospital to establish the efficacy and safety of GLP-1. In outside-hospital studies, GLP-1 or vehicle
was self-administered double-blind before meals with usual insulin for five consecutive days by five
males and three females with well-controlled C-peptide-negative type 1 diabetes. Capillary blood
glucose values were self-monitored before meals, at 30 and 60 min after breakfast and supper, and
at bedtime. Breakfast tests with GLP-1 were conducted on the day before and on the day after 5-
day studies. Paired t-tests and ANOVA were used for statistical analysis.
Results: In 8-hour studies time-averaged incremental (delta) areas under the curves(AUC) for
plasma glucose through 8 hours were decreased by GLP-1 compared to vehicle (3.2 ± 0.9, mean ±
se, vs 5.4 ± 0.8 mmol/l, p < .05), and for pancreatic polypeptide, an indicator of gastric emptying,
through 30 min after meals (4.0 ± 3.1 vs 37 ± 9.6 pmol/l, p < .05) with no adverse effects.
Incremental glucagon levels through 60 min after meals were depressed by GLP-1 compared to
vehicle (-3.7 ± 2.5 vs 3.1 ± 1.9 ng/l, p < .04). In 5-day studies, AUC for capillary blood glucose levels
were lower with GLP-1 than with vehicle (-0.64 ± 0.33 vs 0.34 ± 0.26 mmol/l, p < .05). No assisted
episode of hypoglycaemia or change in insulin dosage occurred. Breakfast tests on the days
immediately before and after 5-day trials showed no change in the effects of GLP-1.
Conclusion: We have demonstrated that subcutaneous GLP-1 can improve glucose control in
type 1 diabetes without adverse effects when self-administered before meals with usual insulin
during established intensive insulin treatment programs.
Background
The pharmacological actions of truncated glucagon-like
peptide-1 (GLP-1), including stimulation of insulin re-
lease, suppression of glucagon release, and inhibition of
gastric emptying, have provided the rationale for its as-
sessment as a therapeutic agent for diabetes, with
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attention largely directed to type 2 diabetes [1]. Acute
studies with subcutaneous injections of GLP-1 in non-in-
sulin-treated type 2 diabetes showed that the peptide can
reduce glucose excursions after meals, and longer-term
studies showed that administration of subcutaneous in-
jections of GLP-1 before meals through periods up to sev-
eral weeks can reduce the mean blood glucose levels in
patients with type 2 diabetes in suboptimal blood glucose
control, without clinical adverse effects [2,3].
In type 1 diabetes, reduction of the blood glucose level
following a meal was demonstrated with continuous in-
travenous infusion of GLP-1 through a period of three
hours after starting breakfast, with concurrent administra-
tion of insulin by closed-loop programmed infusion [4].
The reduction of the glucose excursion with concurrent re-
duction of insulin delivery in this study was taken as evi-
dence of enhancement of insulin sensitivity, but
interpretation did not take account of inhibition of gastric
emptying. In a further study of type 1 diabetes, virtually
complete suppression of glycemic excursions was pro-
duced with intravenous infusion of GLP-1 during and af-
ter breakfast in volunteers who did not take their premeal
insulin injection; this effect was attributed largely to inhi-
bition of gastric emptying [5]. Reduction of fasting hyper-
glycaemia in type 1 diabetes by intravenous infusion of
GLP-1 was attributed mainly to reduced glucagon levels
[6]. We also studied the effects of subcutaneous injection
of GLP-1 in volunteers with type 1 diabetes, some of
whom had residual insulin secretion [7]. After ingestion
of a standard liquid test meal preceded by subcutaneous
injection of GLP-1 and the usual insulin dose, glycemic
excursions were reduced in volunteers with negligible re-
sidual insulin secretion as well as in those with measura-
ble responses of plasma C-peptide to the meal.
In the present study we examined the potential of GLP-1
to improve control of plasma glucose in type 1 diabetes
during intensive insulin therapy in subjects who had no
detectable residual endogenous insulin secretion. Dose-
finding studies were employed to select a dose of GLP-1
that apparently delayed gastric emptying through approx-
imately 30 min after beginning a meal. This dose was used
before breakfast and lunch in 8-hour studies with self-se-
lected diet-conforming meals to determine the safety and
efficacy of GLP-1 under these conditions. The therapeutic
potential of GLP-1 was further investigated in 5-day stud-
ies in which subcutaneous GLP-1 was self-administered
before meals under conditions of normal activity outside
hospital.
Methods
All volunteers had type 1 diabetes with no detectable en-
dogenous insulin response (meal-stimulated C-peptide <
0.10 nmol/l) and continued established programs of in-
tensive insulin therapy using multiple daily injections of
insulin or continuous subcutaneous insulin infusions, Ta-
ble 1. In dose-finding studies subcutaneous abdominal
injections of vehicle, 0.32, 0.63, or 1.25 µg/kg GLP-1 were
administered with usual insulin before breakfast meals
starting between 7:30 and 8:00 AM on different occasions
at least 7 days apart after overnight fast. For 8-hour studies
after overnight fast, volunteers received their usual dose of
insulin, and either 0.63 µg/kg GLP-1, or vehicle, by subcu-
taneous injection in the abdomen immediately before
breakfast starting between 7:30 and 8:00 AM, and again
before lunch four hours later. Meals were self-selected ac-
cording to individually prescribed diets, and were identi-
cal for each pair of studies. In all studies blood samples
were obtained at timed intervals from an intravenous can-
nula in a superficial forearm vein, collected in heparinized
tubes containing aprotinin, held on ice, processed at 4°C,
and stored at -70°C. In paired double-blind 5-day studies
with 0.63 µg/kg subcutaneous GLP-1 or vehicle volunteers
injected a coded dose of GLP-1 or vehicle before each
meal over five consecutive days. Volunteers used their es-
tablished insulin treatment programs, which included
predetermined algorithms for adjustment of insulin dos-
age before meals. Vials of GLP-1 or vehicle were stored in
home freezers and carried in an ice pack during each day
of the study. We established that GLP-1 stored in a home
freezer maintained its biological activity with respect to re-
sponses of glucose and pancreatic polypeptide. Volun-
teers recorded all insulin doses and capillary blood
glucose values before meals, at 30 and 60 min after break-
fast and supper, and at bedtime. Self-determined home
blood glucose values on day five correlated with laborato-
ry values for the same samples with R2 0.94. To ascertain
any modification of the effects of GLP-1 following repeat-
ed subcutaneous administration, breakfast tests with 0.63
µg/kg GLP-1 were conducted on the day before and on the
day after each five-day study. Volunteers gave signed in-
formed consent to protocols approved by the University
of Western Ontario Research Ethics Board for Health Sci-
ences Research Involving Human Subjects.
Synthetic human tGLP-1(7-36)amide (Bachem, Torrance,
CA) was dissolved in 0.05% human serum albumin in sa-
line, sterile-filtered, tested for sterility and pyrogens, and
stored at -20°C. The concentration of GLP-1 was based on
weight corrected for the peptide content given by the
manufacturer. Plasma glucose concentrations were deter-
mined with a Beckman Glucose Analyzer II (Beckman,
Palo Alto, CA). Plasma samples were assayed for pancre-
atic polypeptide with 125I-pancreatic polypeptide and an-
tiserum 615/1054 B-248-19 (RE Chance, Lilly,
Indianapolis, IN), for glucagon with 125I-glucagon and
antibody 04A (RH Unger, Dallas, TX), and for C-peptide
with 125I-C-peptide and antibody 7309 (Peninsula Labo-
ratories Inc, Belmont CA). Free immunoreactive insulinBMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/3
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was measured with 125I-insulin and antibody from P.
Wright, Cambridge, UK, in serum extracted with polyeth-
ylene glycol [8]. Intraassay variability was less than 8% for
all radioimmunoassays. Interassay variabilities of 9% for
pancreatic polypeptide, 16% for glucagon, 12% for C-
peptide, and 24% for free immunoreactive insulin, were
corrected with standard values for control samples run in
each assay. Plasma lactate levels were determined with a
YSI analyzer (Yellow Springs Instrument Co, Yellow
Springs OH). Data are presented as mean values ± SE. In-
cremental (delta) areas under curves were calculated geo-
metrically for stated time periods and time-averaged by
dividing by the total elapsed times. Statistical significance
of differences between mean values was determined by
two factor ANOVA and two-tailed paired t-tests. A P value
of less than 0.05 was considered statistically significant.
Results
Dose Effect of GLP-1
Incremental (delta) excursions of plasma glucose through
3 hours, pancreatic polypeptide responses through 30
min, and glucagon responses through 60 min after meals
were reduced in a dose-dependent manner by GLP-1, Fig-
ure 1 and Table 2. The dose of 0.63 µg/kg GLP-1 was se-
lected for further studies because it was sufficient to delay
gastric emptying through 30 min but did not cause the ab-
dominal discomfort or nausea occasionally associated
with higher doses.
Eight-hour Studies
In 8-hour studies in-hospital, plasma glucose, pancreatic
polypeptide, and glucagon responses to meals were de-
pressed by GLP-1 compared with vehicle, Figure 2, Table
3. Plasma glucose values differed for GLP1 and vehicle in
a time-dependent manner through eight hours as shown
by two-factor ANOVA with replication, P < .0001. The
mean values for time-averaged incremental areas under
the curves for free immunoreactive insulin did not differ
over eight hours for studies with GLP-1(158 ± 39 pmol/l)
and vehicle(136 ± 31). There were also no detectable dif-
ferences between levels of plasma lactate on the two occa-
sions. No adverse effects or episodes of hypoglycaemia
were noted. There were no systematic changes in the insu-
lin treatment algorithms, or in the doses of insulin given
according to these algorithms.
Five-Day Studies
Time-averaged incremental areas under the curves for cap-
illary blood glucose levels from breakfast to lunch and
from supper to bedtime were lower during five days with
GLP-1 than five days with vehicle (-0.64 ± 0.33 vs 0.34 ±
0.26 mmol/l, P < .05), Figure 3. Fasting capillary blood
glucose levels did not differ for five days with GLP-1 com-
pared with five days with vehicle (8.0 ± 0.64 vs 7.7 ± 0.64
mmol/l). No episodes of assisted hypoglycaemia occurred
nor were there any changes in insulin dosage (0.77 ± 0.07
vs 0.74 ± 0.06 U/kg/day). Injection of GLP-1 elicited no
symptoms during the at-home study, and volunteers re-
ported normal appetite and food intake.
The standardized breakfast tests on the day before and on
the day after the 5-day trials showed no modification of
the effect of GLP-1 on plasma glucose and pancreatic
polypeptide responses, Table 4. Mean time-averaged in-
cremental areas under the curves for free immunoreactive
insulin through three hours did not differ in the tests be-
fore and after the 5-day studies(178 ± 49 and 139 ± 29
pmol/l before and after 5-day studies with GLP-1, P =
0.19; 135 ± 40 and 167 ± 46 before and after 5-day studies
with vehicle, P = 0.42).
Discussion
We have demonstrated the efficacy and apparent safety of
subcutaneous injection of GLP-1 together with insulin for
reduction of glucose excursions after meals in type 1 dia-
betes, in volunteers with no detectable response of plasma
C-peptide to the meals. We have also demonstrated that
subcutaneous GLP-1, self-administered before meals, im-
proved glycemic control in type 1 diabetes through five
days with no modification of effects. All volunteers were
receiving intensified insulin therapy using multiple daily
Table 1: Characteristics of subjects
Dose Study 8-Hour Study 5-Day Study
N1 5 9 8
Sex 9M/6F 4M/5F 5M/3F
A g e ,  y4 0  ±  43 6  ±  53 4  ±  3
BMI 24.6 ± 0.9 24.7 ± 0.9 25.4 ± 1.3
Duration of T1D, y 16 ± 3 18 ± 5 15 ± 4
Insulin dose, U/kg/d 0.66 ± 0.10 0.79 ± 0.15 0.73 ± 0.07
Fasting glucose, mmol/l 5.9 ± 0.5 5.5 ± 0.6 6.9 ± 0.6
A1c, % 6.5 ± 0.3 6.5 ± 0.3 6.5 ± 0.4BMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/3
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Figure 1
Dose-effect of glucagon-like peptide 1. Plasma glucose, pancreatic polypeptide(HPP), and incremental glucagon responses 
to breakfast with subcutaneous injection of varying doses of GLP-1 with usual insulin in volunteers with type 1 diabetes.
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injections or continuous subcutaneous insulin infusion,
according to current guidelines, with good metabolic con-
trol demonstrated by their mean fasting plasma glucose,
fasting capillary blood glucose, and haemoglobin A1c lev-
els.
Other studies in humans with type 1 diabetes suggest that
GLP-1 may have metabolic effects that develop during
prolonged parenteral delivery of the peptide [1,4,9]. The
possibility that such effects can develop after a brief expo-
sure to GLP1 with continuing hyperglycaemia, as in the
present study, cannot be excluded. Given the absence of
endogenous secretion of insulin and lack of evidence of
an effect of GLP-1 on the clearance of exogenous insulin,
we infer that the glycemic effect of the peptide was not
mediated by increased exposure to insulin. However, de-
lay of delivery of a meal relative to administration of insu-
lin by 15 minutes or more may itself be sufficient to
account for prolonged enhancement of the glycemic effect
of insulin [10]. We suggest that delay of gastric emptying
by GLP-1, with time course indicated by postponement of
the pancreatic polypeptide response for approximately 30
min from initiation of meals, was the major factor in de-
termination of the glucose effect of the peptide.
It has been shown that GLP-1 can inhibit glucagon secre-
tion in normal humans, and in volunteers with type 1 or
type 2 diabetes, and this action may contribute to reduc-
tion of glucose responses to meals [1]. In our results and
other studies of type 1 diabetes under good metabolic
control with intensive insulin therapy [7], an abnormal
rise of plasma glucagon did not occur after meals. Howev-
er in the present study GLP-1 suppressed plasma glucagon
levels below those observed after meals with injection of
the vehicle. Thus it is possible that inhibition of glucagon
secretion contributed to the reduction of glucose excur-
sions in the present study.
The 5-day studies of self-administration of GLP-1 had lim-
itations dictated by practical considerations. Self-determi-
nation of blood glucose levels was confined to testing
before meals and at 30 and 60 min after breakfast and
supper, but was not undertaken across lunchtime because
this was considered impractical by some of the volunteers.
Nevertheless reduction of reported values for capillary
blood glucose levels after meals in these studies is consist-
ent with the reduction in plasma glucose values observed
in 8-hour studies in-hospital. Thus self-administration of
GLP-1 over five days was effective in improving glycemic
control.
The 5-day study was not long enough to modulate long-
term indices of glycemic control such as glycated hemo-
globin. However the results suggest that long-term use of
GLP-1 may result in clinically significant reductions in
A1c levels in patients in whom further intensification of
insulin therapy is limited by the risk of hypoglycaemia.
The volunteers in the present studies were already on es-
tablished intensive insulin regimens and were well-con-
trolled as shown by the low values for fasting glucose and
hemoglobin A1c. Many people with type 1 diabetes mel-
litus receiving apparently optimized insulin treatment fail
to achieve acceptable levels of hemoglobin A1c, and in
such patients further improvement of glycemic control
might also be attainable with GLP-1.
In the present study it is notable that the effect on glyc-
emic control was not associated with systematic change in
insulin dosage or with an increase in symptomatic hy-
poglycaemia. The insulin treatment programs of the vol-
unteers were not modified in order to avoid confounding
effects of such changes on interpretation of the findings.
However further studies with GLP-1 agents should also as-
sess the possible benefits of concurrent optimization of
the insulin treatment program and the dosage of GLP-1.
GLP-1 is known to be degraded rapidly in the circulation
and has a short duration of action. Inhibitors of degrada-
tive dipeptidases have been used to prolong the duration
of action of GLP-1 [11] but these agents may have adverse
Table 2: Dose effect of glucagon-like peptide 1. Effects of graded doses of GLP-1 and usual insulin before breakfast in volunteers with 
type 1 diabetes with no endogenous insulin secretion, with number of subjects studied at each dose. Time-averaged incremental (delta) 
responses (area under the curve divided by total time) of plasma glucose through 3 hours, pancreatic polypeptide(HPP), 0 to 30 min, 
and glucagon, 0 to 60 min, mean ± se. Polynomial regression analysis (R2) for dose vs incremental responses.
Dose µg/kg n Glucose mmol/l HPP pmol/l Glucagon ng/l
0 15 6.5 ± 0.8 27.4 ± 4.6 11.9 ± 3.7
0.32 9 5.8 ± 1.7 14.1 ± 6.4 8.5 ± 4.5
0.63 12 5.2 ± 0.8 3.1 ± 2.2 6.6 ± 2.5
1.25 11 4.7 ± 0.8 1.7 ± 0.89 5.1 ± 6.7
R2 0.99 0.99BMC Endocrine Disorders 2003, 3 http://www.biomedcentral.com/1472-6823/3/3
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Figure 2
Eight-hour studies with glucagon-like peptide 1. Plasma glucose, pancreatic polypeptide(HPP), incremental glucagon, free 
immunoreactive insulin, and lactate responses to breakfast and lunch with subcutaneous injection of 0.63 µg/kg GLP-1 (closed 
circles) or vehicle (open circles) immediately before meals in volunteers with type 1 diabetes, n = 9.
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Table 3: Eight-hour studies with glucagon-like peptide 1. Effects of vehicle or 0.63 µg/kg subcutaneous GLP-1 and usual insulin at 
breakfast and lunch in paired studies in 9 volunteers with type 1 diabetes with no endogenous insulin secretion. Time-averaged 
incremental values (area under the curve divided by time) for plasma glucose through eight hours and for plasma pancreatic 
polypeptide from 0 to 30 min for both meals (HPP), and mean values for incremental plasma glucagon through 60 min for both meals, 
mean ± SE.
Glucose mmol/l HPP pmol/l Glucagon ng/l
Vehicle 5.4 ± 0.8 37 ± 9.6 3.1 ± 1.7
GLP1 3.2 ± 0.9* 4.0± 3.1* -3.7 ± 2.5*
*P < .05, paired t-tests for GLP-1 compared to vehicle
Figure 3
Five-day studies with glucagon-like peptide 1. Capillary blood glucose values, mean ± SE, before meals (ac), at 30 and 60 
min after breakfast and supper, and at night (HS), over five days with self-administered subcutaneous GLP-1 and usual insulin 
before meals (closed circles) and over five days with vehicle before meals (open circles) in volunteers with type 1 diabetes, n = 
8. *P <.05 for time points, paired t-tests.
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effects due to non-specific activity. Analogues of GLP-1
with longer duration of action [12,13] have been reported
to have antidiabetic effects and may be more effective
than GLP-1 in well-controlled type 1 diabetes. We suggest
that GLP-1 agonists as potential congeners with insulin in
treatment of diabetes may improve glycemic control be-
yond the level safely achieved with insulin therapy. This
possibility should be explored in studies of sufficient du-
ration to assess indices of long-term glycemic control.
Conclusions
GLP-1 administered by subcutaneous injection before
meals improves glucose control in type 1 diabetes through
five days with no modification of effects. The necessary
dose, and the safety and efficacy of GLP-1 in patients with
no endogenous insulin secretion and with well-controlled
type 1 diabetes have been demonstrated in the present
study. GLP-1 agonists may be useful in enhancement of
glucose control in type 1 diabetes during optimized treat-
ment with insulin.
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